Medtronic starts Engager trial in Europe; Clarimed.com aims for easier access to adverse event info;

> Medtronic ($MDT) has begun its European pivotal trial to pursue the CE Mark for the Engager transcatheter aortic valve implantation system in patients suffering from severe aortic stenosis. The 150-person trial will be conducted at 11 centers in Germany, Israel, France, Belgium and Switzerland. Medtronic release

> Medical device safety and quality site Clarimed.com will sift through the jargon and hard to find info in the FDA's medical device adverse event database and organize it so patients can find what they need to know to make choices for their own treatments. It also aims to give healthcare professionals, consultants and IT staffers faster access to adverse event information. News

> Aribex, which focuses on handheld x-ray technologies, has appointed Ken Kaufman as president and CFO. Founder Clark Turner will retain his title as chairman and CEO, and assume responsibility as chief technical officer. Aribex release

> Titan Spine has received FDA clearance to launch its Endoskeleton TAS system, consisting of an ALIF device with integrated fixation screws. Titan Spine release

> Boston Sci's Guidant unit has agreed to pay $9.25 million to resolve False Claims Act allegations. The government alleges the company inflated the cost of replacement pacemakers and defibrillators to federal healthcare programs. DOJ release       

And Finally... Great Dane puppy Cooper was headed for death or life with a perpetual limp. But CSU small animal orthopedic surgeon Ross Palmer went to work on Cooper's badly damaged right rear tibia. Palmer decided to cut and then straightened Cooper's shin bone using an orthopedic device not available in the U.S. Story (with photo)  

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.